bicyclo<4.4.0>dec-8,10-dien-2-one | 115960-76-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: bicyclo<4.4.0>dec-8,10-dien-2-one
• 英文别名: Tetrahydronaphthalene-one；3,4,4a,5-tetrahydro-2H-naphthalen-1-one
• CAS: 115960-76-4
• 化学式: C₁₀H₁₂O
• 分子量: 148.205
• InChiKey: QFNABHBYVSJWLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2-二氢萘 、 、 bicyclo<4.4.0>dec-8,10-dien-2-one 、 7-溴-4,4-二甲基-1-四氢萘酮 、 苯硫酚 在 四氯化钛 作用下， 以 四氢呋喃 、 三乙胺 为溶剂， 以to provide the intermediate 4,4-dimethyl-7-bromo-1-phenylthio-3,4-dihydronaphthalene (Compound A35)的产率得到2-bromo-5,6-dihydro-5,5-dimethyl-8-(phenylthio)-naphthalene
  参考文献：
  名称：

  O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

  摘要：

  式子1中的符号具有申请中所述的含义，该化合物具有类视黄醇或类视黄醇拮抗剂的生物活性。

  公开号：

  US20020099038A1
• 作为产物：
  描述：

  (4aR,8S,8aR)-8-methoxy-3,4,4a,5,8,8a-hexahydro-2H-naphthalen-1-one 以88%的产率得到
  参考文献：
  名称：

  FRINGUELLI, FRANCESCO;MINUTI, LUCIO;RADICS, LAJOS;TATICCHI, AIDO;WENKERT,+, J. ORG. CHEM., 53,(1988) N 19, C. 4607-4610

  摘要：

  DOI：

文献信息

• 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
  申请人：——

  公开号：US20030073850A1

  公开（公告）日：2003-04-17

  Compounds of formula I 1 are useful in treating diseases prevented by or ameliorated with &agr; 1A agonists. Also disclosed are &agr; 1A agonist compositions and a method of activating &agr; 1 adrenoceptors in a mammal.

  公式I的化合物在治疗由&agr; 1A激动剂预防或改善的疾病中很有用。还公开了&agr; 1A激动剂组合物和在哺乳动物中激活&agr; 1肾上腺素受体的方法。
• 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
  申请人：Sinha Santosh

  公开号：US20050004213A1

  公开（公告）日：2005-01-06

  Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.

  式中变量的含义如规范中定义的那样，这些化合物能够降低糖尿病哺乳动物的血清葡萄糖水平，而不会出现降低血清甲状腺素水平和短暂增加甘油三酯水平的不良副作用。
• Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin
  申请人：The Board of Regents of the University of Nebraska

  公开号：EP0523289A1

  公开（公告）日：1993-01-20

  To produce doxorubicin and its analogues, methyl 3alpha, 5alpha-dihydroxy-5beta-(trimethylsilylethynyl)-2alpha-nitromethylcyclohexane-1beta-carboxylate acetonide is condensed with 1,4-dihydro-4,4,5-trimethoxy-1-oxonaphthalene in the presence of 1,8-diazabicyclo-[5.4.0]undec-7-ene in an aprotic solvent to produce 3-[(2beta-carbomethoxy-4beta-ethynyl-4alpha, 6alpha-(di-0-isopropylidenyl)cyclohexanyl-1-yl]-nitromethyl-4,4,5-trimethoxy-1-oxo-1,2,3,4-tetrahydronaphthalene, which is cyclized to produce 9beta-ethynyl-12-hydroxy-7alpha,9alpha-(di-0-isopropylidenyl)-6-nitro-4,5,5-trimethoxy-5,5a,6,6a,7,8,9,10,10a,11-decahydro-11-naphthacenone. The decahydro-11-naphthacenone is converted to 7alpha-9alpha,(di-0-isopropylidenyl)-4,5-dimethoxy-9beta-ethynyl-12-hydroxy-6-nitro-6,6a,7,8,9,10,10a,11-octahydro-11,-naphthacenone. The octahydro-11-naphthacenone is oxidized to 7alpha-9alpha, (di-0-isopropylidenyl)-9beta-ethynyl-11-hydroxy-4-methoxy-6-nitro-7,8,9,10,-tetrahydro-5,12-naphthacenedione which is converted to 6-desoxy-6-nitrodaunomycinone, daunomycinone and related 6-substituted analogues of daunomycinone.

  为了生产阿霉素及其类似物，需要将甲基3α，5α-二羟基-5β-(三甲基硅乙炔基)-2α-硝基甲基环己烷-1β-羧酸乙酸酯与1,4-二氢-4,4,5-三甲氧基-1-氧代萘醌在无极性溶剂中，在1,8-二氮杂双环[5.4.0]十一烷-7-烯的存在下进行缩合反应，产生3-[(2β-羧甲氧基-4β-乙炔基-4α，6α-(二异丙亚基)环己基-1-基]-硝基甲基-4,4,5-三甲氧基-1-氧代-1,2,3,4-四氢萘烯，然后将其环化产生9β-乙炔基-12-羟基-7α，9α-(二异丙亚基)-6-硝基-4,5,5-三甲氧基-5,5a,6,6a,7,8,9,10,10a,11-十氢-11-萘酮。 十氢-11-萘酮转化为7α-9α，(二异丙亚基)-4,5-二甲氧基-9β-乙炔基-12-羟基-6-硝基-6,6a,7,8,9,10,10a,11-八氢-11-萘酮。 八氢-11-萘酮氧化为7α-9α，(二异丙亚基)-9β-乙炔基-11-羟基-4-甲氧基-6-硝基-7,8,9,10,-四氢-5,12-萘醌，然后转化为6-去氧-6-硝基多柔霉素酮，多柔霉素酮及相关的多柔霉素酮6-取代物。
• [EN] UROTENSIN II RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR DE L'UROTENSINE II
  申请人：ACADIA PHARM INC

  公开号：WO2003104216A1

  公开（公告）日：2003-12-18

  Disclosed are compounds of Formula I, or salts or prodrugs thereof, complexed with a human urotensin II receptor as defined herein. Also disclosed are compounds of Formula II, or salts or prodrugs thereof, as defined herein. Also disclosed are methods of modulating the activity of a urotensin II receptor using a compound of Formula I, or a compound of Formula II, or salts or prodrugs thereof. In addition, methods of treating diseases related to the activity of urotensin II receptors are disclosed.

  本文披露了根据本文所定义的与人类尿嘧啶 II 受体形成络合物的 Formula I 化合物，或其盐或前药。还披露了根据本文所定义的 Formula II 化合物，或其盐或前药。还披露了使用 Formula I 化合物、Formula II 化合物、或其盐或前药来调节尿嘧啶 II 受体活性的方法。此外，还披露了治疗与尿嘧啶 II 受体活性相关疾病的方法。
• [EN] N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS<br/>[FR] AMINOTETRALINES N SUBSTITUEES, LIGANDS DU RECEPTEUR Y Y5 DU NEUROPEPTIDE SERVANT AU TRAITEMENT DE L'OBESITE ET D'AUTRES TROUBLES
  申请人：ORTHO-MCNEIL PHARMACEUTICAL, INC.

  公开号：WO1999055667A1

  公开（公告）日：1999-11-04

  (EN) $g(b)-Aminotetralin derivatives of formula (1): which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a $g(b)-aminotetralins derivative as the active ingredient are described. The $g(b)-aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.(FR) L'invention porte sur des dérivés d'aminotétraline de formule (1) ligands du récepteur Y Y5 (NPY5) du neuropeptide, sur leurs procédés de préparation, et sur des compositions pharmaceutiques les contenant comme principe actif. Les aminotétralines servent pour le traitement de troubles et de maladies liées au sous-type Y5 du récepteur NPY.

  (中文) 描述了公式（1）的$g(b)-氨基四环素衍生物，它们是神经肽Y Y5（NPY5）受体的配体，以及制备方法和含有$g(b)-氨基四环素衍生物作为活性成分的制药组合物。$g(b)-氨基四环素衍生物对于治疗与NPY受体亚型Y5相关的疾病和疾病非常有用。